The greatest barrier to successful @entity447 care in resource-rich countries is the development of inhibitors to therapeutic factor VIII. @entity1 with inhibitors suffer through @entity548 and @entity16 as well as frequent venepuncture. Costs associated with inhibitors are beyond many healthcare systems. Over the last two decades, there has been no improvement in our ability to reduce inhibitor development. Current strategies based on early prophylaxis and avoidance of immunological danger signals have given rise to conflicting results. Registry data suggest an increasing problem. Our understanding of the immunological systems involved in inhibitor formation should inform efforts to prevent inhibitors. Great efforts with @entity19 models are being undertaken in this field. However, there is no guarantee of the availability of any new agents arising from experimental work in the near future. Global immunomodulatory agents may be one solution. Compounds with a long history of use in inflammatory conditions have demonstrated efficacy in preventing antibodies to protein therapeutics both in animal models and in @entity1 . As these compounds have a long history of use in @entity1 , including babies, it may be that these agents offer an option for reducing inhibitor formation in previously untreated @entity1 .

Strategies for reducing inhibitor formation in severe XXXX .

@entity1 :: ('9606', 'Species') :: ['humans', 'patients', 'Children'] @entity548 :: ('MESH:D006470', 'Disease') :: ['increased bleeding'] @entity447 :: ('MESH:D006467', 'Disease') :: ['haemophilia A'] @entity19 :: ('10090', 'Species') :: ['mouse'] @entity16 :: ('MESH:D009422', 'Disease') :: ['joint damage']
@entity447 :: (MESH:D006467,Disease) :: ['haemophilia']
